ROCHESTER, N.Y., Oct. 30, 2015 — Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including Huntington’s disease, provided corporate sponsorship and presented information on its current SIGNAL clinical trial (phase 2 trial of VX15 antibody in Huntington’s disease) at the 2015 Huntington Study Group Annual Meeting held October 21 through October 24, 2015 in Tampa, Fl.
The Huntington Study Group (HSG), a not-for-profit organization, is focused on advancing knowledge about the cause, disease progression, and treatments for Huntington disease (HD) and related disorders. Over the past 20 years, HSG has hosted an annual, internationally recognized forum for training and education of HD researchers and for presentation of new research findings and treatments.
At the annual HSG meeting, Andrew Feigin, M.D., who is the Director, Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research, and the Principle Investigator for the SIGNAL trial, presented an overview of the design of the trial at the “HD Trial Roundup” session. Dr. Maurice Zauderer, President and CEO of Vaccinex, Inc., presented the science behind the Company’s SIGNAL trial at the “HD Innovators forum.”
The SIGNAL trial, involving some twenty participating clinical sites across the United States, is a phase 2 study to assess the safety, tolerability and efficacy of anti-semaphorin 4D antibody VX15/2503 (“VX15”) in Huntington’s disease (“HD”), a neurodegenerative genetic disorder that typically manifests in mid-adult life. The SIGNAL trial is being performed with the assistance of the Huntington Study Group and is designed to evaluate VX15 antibody in up to 84 subjects with late-prodromal or early-manifest HD. The SIGNAL trial is based on the Company’s prior research of neurodegenerative disease mechanisms, where it was demonstrated in preclinical models that semaphorin 4D (“SEMA4D”) triggers activation of both microglia and astrocytes, the innate inflammatory cells of the central nervous system. The chronic activation of microglia and astrocytes has been implicated as a potentially important disease mechanism in HD, progressive multiple sclerosis (“MS”) and other neurodegenerative disorders. VX15 antibody is designed to block the functional activity of SEMA4D. The SIGNAL clinical trial will build upon preclinical studies in an animal model of HD and safety data from a Phase 1 dose-escalation clinical trial of VX15 in MS patients that was completed in November 2014.
About Vaccinex, Inc.
Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases. The Company has completed phase 1 clinical trials in solid tumors and multiple sclerosis and is currently engaged in a phase 2 clinical trial in Huntington’s disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed in mammalian cells and have desirable solubility and stability properties. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.
CONTACT: Vaccinex email@example.com
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements reflecting the current beliefs and expectations of management. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions, as well as other words or expressions referencing future events, conditions or circumstances, are intended to identify forward-looking statements. Forward-looking statements contained in this press release include statements about the initiation of a Phase 2 clinical trial for the Company’s lead monoclonal antibody, VX15/2503. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including as a result of the inherent challenges in clinical development. All forward-looking statements are based on Vaccinex’s expectations and assumptions as of the date of this press release, and actual results may differ materially. Except as required by law, Vaccinex expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.